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AIMS
Although high blood pressure (BP) is common in acute stroke and associated with poor outcome, the Efﬁcacy of Nitric Oxide in
Stroke (ENOS) trial showed no beneﬁcial effect of antihypertensive treatment in this situation. Antihypertensive agents have
accentuated effects in dehydrated patients. We assessed the impact of dehydration on haemodynamics, the effects of
antihypertensive treatment, and prognosis in the ENOS trial.
METHODS
ENOS randomized 4011 patients with acute stroke and raised systolic BP to a glyceryl trinitrate (GTN) patch or no GTN patch, and
to continue or to stop existing antihypertensive treatment within 48 h of onset. The primary outcome was functional outcome
(modiﬁed Rankin Scale, mRS) at day 90. Blood markers of dehydration at baseline were collected at two sites (n = 310) and their
relationship with haemodynamics and outcome was assessed.
RESULTS
There were no signiﬁcant associations between dehydration markers and fall in blood pressure from baseline to day 1, and no
signiﬁcant interaction with allocated treatment. Overall, increasing urea was associated with an unfavourable shift in mRS [odds
ratio 3.43, 95% conﬁdence interval (CI) 1.42, 8.32; P = 0.006] and increased risk of death at day 90 (hazard ratio 4.55, 95% CI
1.51, 13.66; P = 0.007).
CONCLUSIONS
Blood pressure-lowering treatment was safe in dehydrated patients, with no precipitous changes in BP, thus supporting its use in
acute stroke prior to blood markers of dehydration becoming available. Increased baseline urea was associated with poor prog-
nosis after stroke.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Both high blood pressure (BP) and dehydration are common and independently associated with poor clinical outcomes
following acute stroke.
• Antihypertensive agents may have accentuated effects in dehydrated patients, but their effects in dehydrated acute stroke
patients are unclear.
WHAT THIS STUDY ADDS
• BP-lowering treatment was safe in dehydrated patients, with no precipitous changes in BP, thus supporting its use in
acute stroke prior to blood markers of dehydration becoming available.
Introduction
High blood pressure (BP) is common in acute stroke and asso-
ciated independently with a poor outcome in both ischaemic
stroke and intracerebral haemorrhage [1]. Lowering elevated
BP is recommended in acute intracerebral haemorrhage [2],
and is safe in ischaemic stroke [3, 4]. Most drug classes that
might be useful for lowering BP (including angiotensin-
converting enzyme inhibitors, angiotensin receptor antago-
nists and nitrates) have accentuated vasodepressant effects
when patients are dehydrated or hypovolaemic [5]. Reduced
circulating volume is also common in stroke, especially if ad-
mission to hospital is delayed, thereby allowing dehydration
to develop. Hypovolaemia may reduce cerebral perfusion and
increase the infarct core in ischaemic stroke [6] and the
perihaematomal ischaemia in intracerebral haemorrhage
[7]. It may also lead to renal impairment and is associated
with venous thromboembolism [8, 9]. As a consequence, de-
hydration has been associated with poor clinical outcomes
following acute stroke [10–12], and adequate hydration after
stroke is recommended in clinical guidelines [8].
The Efﬁcacy of Nitric Oxide in Stroke (ENOS) trial assessed
the effect of transdermal glyceryl trinitrate (GTN) on out-
come in 4011 patients [4]. Overall, GTN did not alter clinical
outcomes, despite lowering BP by 7/3.5 mmHg at day 1 [4],
but when administered within 6 h of stroke onset, GTN im-
proved multiple clinical outcomes at day 90 [13]. The aim of
the present planned substudy was to assess the impact of de-
hydration on haemodynamic changes, effect of blood pres-
sure reduction on clinical outcomes, and prognosis after
stroke.
Methods
The ENOS trial protocol, statistical analysis plan, baseline
characteristics and main trial results have been published
elsewhere [4, 14–16]. In brief, ENOS recruited 4011 people
with acute stroke within 48 h of onset and high systolic BP
(140–220 mmHg), and randomized them to a GTN 5 mg
patch or no patch for 7 days. In addition, participants taking
antihypertensive medication prior to the index event were
randomized to continue or stop these drugs for 7 days. Pa-
tients or relatives/carers gave written consent to participate.
ENOS was registered (ISRCTN99414122) and approved by
ethics committees/competent authorities in all participating
countries.
Biomarkers of dehydration
Biochemical biomarkers were recorded at two sites
(Nottingham City Hospital and Queen’s Medical Centre,
Nottingham, UK), including full blood count (haemoglobin,
red cell count, haematocrit/packed cell volume) and bio-
chemistry (sodium, potassium, urea, creatinine, glucose).
Estimated glomerular ﬁltration rate (eGFR) was calculated
using the Modiﬁcation of Diet in Renal Diseases (MDRD)
equation: 186 × serum creatinine (μmol l–1)–1.154 × age
(years)–0.203 × (0.742 if female) × (1.210 if Black). As ethnicity
was not recorded in ENOS, participants of Black ethnicity will
have an underestimated eGFR.
In addition, we calculated the following markers of dehy-
dration: (i) urea : creatinine (mg dl–1); (ii) 2Na + glucose + urea
(mmol l–1) [17];, and (iii) 2Na + 2K + glucose + urea (mmol l–1)
[18], which are all elevated in dehydrated patients. The latter
two are also formulae for osmolarity. Ethanol may be added to
the calculations, to reﬁne the estimate of osmolarity, but was
not measured in ENOS. Furthermore, ENOS did not routinely
collect information on clinical markers of dehydration, such
as thirst or skin turgor.
Dehydration was deﬁned as: Na > 145 mmol l–1, urea >
7.5 mmol l–1, urea : creatinine ratio >20, calculated
osmolarity >297 mmol l–1, eGFR <30 ml min–1 1.73m–2,
haematocrit >0.54 l l–1 for men and >0.47 l l–1 for women,
and red cell count >6.5 cells μl–1 for men and >5.8 cells μl–1
for women.
Haemodynamic outcomes
Peripheral haemodynamics (BP and heart rate) were measured
at baseline (three measurements) and on days 1 to 7 (two
measurements per day), using a validated automated monitor
(OMRON Healthcare Company, Kyoto, Japan) [19].
Clinical outcomes
The primary outcome (functional outcome) was measured
using the modiﬁed Rankin Scale (mRS, a seven-level ordered
categorical scale, where 0 = independent and 6 = dead) at
day 90. Clinical outcomes included all-cause death at day
90, and headache, hypotension, hypertension at day 7, and
change in the Scandinavian Stroke Scale (SSS, a marker of
neurological improvement) from baseline to day 7. Multiple
secondary outcomes were also assessed at day 90. All day 90
outcomes were assessed centrally by telephone by trained in-
vestigators based at the International Coordinating Centre in
Nottingham; assessors were masked to treatment allocation.
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Table 1
Baseline characteristics of patients enrolled into the Efﬁcacy of Nitric Oxide in Stroke (ENOS) sub-study. Data are are given as number (%) or mean
(standard deviation); comparison by the chi-square test or one-way analysis of variance
Participants
All
310 GTN n No GTN n P Continue n Stop n P
Age (years) 73.2 (11.7) 73.1 (11.7) 158 73.3 (11.7) 152 – 77.0 (9.2) 74 76.1 (8.9) 76 –
Sex, male (%) 169 (54.5) 84 (53.2) 158 85 (55.9) 152 – 36 (48.6) 74 33 (43.4) 76 –
Drugs prestroke (%)
ACE-I 57 (18.4) 26 (16.5) 158 31 (20.4) 152 – 30 (40.5) 74 26 (34.2) 76 –
ARB 18 (5.8) 12 (7.6) 158 6 (3.9) 152 – 7 (9.5) 74 10 (13.2) 76 –
β-receptor antagonist 68 (21.9) 39 (24.7) 158 29 (19.1) 152 – 28 (37.8) 74 36 (47.4) 76 –
Calcium channel blocker 56 (18.1) 34 (21.5) 158 22 (14.5) 152 – 25 (33.8) 74 25 (32.9) 76 –
Diuretic 62 (20) 38 (24.1) 158 24 (15.8) 152 – 24 (32.4) 74 31 (40.8) 76 –
Others 14 (4.5) 11 (7) 158 3 (2) 152 – 8 (10.8) 74 5 (6.6) 76 –
Stroke type, ischaemic (%) 264 (85.2) 131 (82.9) 158 133 (87.5) 152 – 66 (89.2) 74 66 (86.8) 76 –
Stroke severity (SSS, /58) 32.5 (13.9) 32.4 (13.9) 158 32.6 (14) 152 – 33.0 (13.7) 74 32.2 (13.1) 76 –
Stroke syndrome, TACS (%) 124 (40) 70 (44.3) 158 54 (35.5) 152 – 33 (44.6) 74 30 (39.5) 76 –
Systolic blood pressure (mmHg) 166.6 (20.1) 167.7 (19.1) 158 165.4 (21.1) 152 – 166.9 (19.9) 74 165.0 (18.0) 76 –
Diastolic blood pressure (mmHg) 89.1 (14.3) 89.7 (15.5) 158 88.4 (12.9) 152 – 87.1 (14.3) 74 85.2 (12.6) 76 –
Heart rate (bpm) 75.4 (14.4) 74.9 (13.8) 158 76 (14.9) 152 – 77.3 (16.4) 74 73.6 (14.1) 76 –
Time, onset to randomization (h) 27.6 (12.1) 27.5 (12.2) 158 27.8 (12.0) 152 – 25.4 (11.7) 74 25.6 (12.0) 76 –
Blood analyses
Haematocrit (l l–1) 0.42 (0.04) 0.42 (0.04) 152 0.41 (0.04) 142 0.33 0.41 (0.04) 69 0.41 (0.04) 70 0.61
Haemoglobin (g l–1) 139 (16.3) 140 (16.5) 152 138 (16.1) 142 0.30 136 (14.2) 69 139 (15.0) 70 0.31
Red cell count (1012 l–1) 4.6 (0.5) 4.6 (0.5) 152 4.6 (0.5) 142 0.54 4.5 (0.5) 69 4.6 (0.5) 70 0.56
Sodium (mmol l–1) 138.3 (3.6) 138.3 (3.9) 154 138.4 (3.4) 143 0.69 138.1 (4.0) 70 138.5 (3.8) 72 0.57
Potassium (mmol l–1) 4.1 (0.5) 4.1 (0.5) 149 4.2 (0.4) 141 0.16 4.0 (0.5) 67 4.0 (0.5) 71 0.92
Urea (mmol l–1) 6.5 (2.6) 6.4 (2.6) 154 6.6 (2.6) 143 0.45 7.1 (2.7) 70 7.0 (2.2) 72 0.87
Creatinine (μmol l–1) 94.4 (32) 93.1 (25.3) 154 95.8 (37.9) 143 0.47 98.6 (43.4) 70 97.7 (25.4) 72 0.88
eGFR (ml min–1 1.73 m2) 69.7 (20.8) 69.5 (19.7) 154 69.9 (22.1) 143 0.85 65.4 (19.3) 70 63.2 (18.3) 72 0.51
Glucose (mmol l–1) 6.7 (1.9) 6.7 (1.9) 126 6.7 (1.9) 114 0.93 6.8 (1.9) 59 6.9 (1.7) 52 0.87
Urea : creatinine (mg dl–1) 17.4 (5.3) 17.0 (4.6) 154 17.8 (5.9) 143 0.21 18.4 (4.9) 70 18.0 (4.6) 72 0.67
Osmolarity A (mmol l–1) 289.6 (7.7) 288.9 (8.5) 126 290.3 (6.7) 112 0.17 289.0 (8.9) 59 291.5 (7.7) 51 0.13
Osmolarity B (mmol l–1) 297.8 (7.8) 297.2 (8.7) 122 298.6 (6.7) 111 0.17 296.8 (9.3) 56 299.3 (7.8) 50 0.14
Dehydration markers
Sodium >145 mmol l–1 (%) 3 (1) 3 (1.9) 154 0 (0) 143 0.09 1 (1.4) 70 1 (1.4) 72 0.98
Urea >7.5 mmol l–1 (%) 69 (23.2) 35 (22.7) 155 34 (23.8) 143 0.83 20 (28.6) 70 25 (34.7) 72 0.43
eGFR <30 ml min–1 1.73 m2 (%) 4 (1.3) 1 (0.6) 154 3 (2.1) 143 0.28 2 (2.9) 70 0 (0) 72 0.15
Urea : creatinine >20 (%) 75 (25.3) 36 (23.4) 154 39 (27.3) 143 0.44 26 (37.1) 70 19 (26.4) 72 0.17
Osmolarity A >297 mmol l–1 (%) 31 (13) 17 (13.5) 126 14 (12.5) 112 0.82 10 (16.9) 59 13 (25.5) 51 0.27
Osmolarity B >297 mmol l–1 (%) 129 (55.6) 62 (51.2) 121 67 (60.4) 111 0.16 30 (53.6) 56 31 (62.0) 50 0.38
Haematocrit >0.54 l l–1 (male),
>0.47 l l–1 (female) (%)
6 (2.0) 6 (3.9) 152 0 (0) 142 0.017 1 (1.4) 69 1 (1.4) 70 0.99
(continues)
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Statistical analysis
Data were analysed by intention-to-treat, in line with the ENOS
trial statistical analysis plan and statistical analyses adopted in
the primary publication [16]. Data are shown as number (%),
median [interquartile range], or mean (standard deviation).
Baseline characteristics between groups were assessed using
the chi-squared test for categorical variables, and one-way
analysis of variance for continuous variables.
Associations between dehydration markers and haemo-
dynamic changes from baseline to day 1 were assessed using
multiple linear regression, after adjustment for age, sex and
allocated treatment, with resultant standardized regression
coefﬁcients (β) given. Interaction P-values were calculated
by adding an interaction term for treatment and dehydration
marker to the models.
Associations between dehydration markers and clinical
outcomes were assessed using Cox proportional hazard re-
gression, binary logistic regression, multiple linear regression
or ordinal logistic regression. The impact of dehydration on
the effect of treatment was assessed by introducing an inter-
action term for treatment and dehydration status to the anal-
yses. Statistical models were adjusted for prognostic baseline
covariates, including age, sex, systolic BP, SSS and time to
randomization. Analyses involving the whole population
were also adjusted for treatment allocation. The resultant
hazard ratio (HR), mean difference (MD) or odds ratio and as-
sociated 95% conﬁdence intervals are given, with signiﬁ-
cance set at P ≤ 0.05. Analyses were performed using SPSS
version 22 (SPSS Inc., Chicago, IL, USA).
Results
The present sub-study included 310 participants (GTN 158,
no GTN 152; continue prestroke antihypertensive agents
74, temporarily stop 76) from two trial sites in Nottingham,
UK. Of these, 294 had data on one or more laboratory mea-
sure of dehydration. Baseline characteristics and biochemical
markers of dehydration are shown in Table 1. Clinical charac-
teristics were well balanced, and blood markers of dehydra-
tion did not differ between randomized groups (GTN vs. no
GTN, or continue vs. stop prestroke antihypertensive agents),
except for raised haematocrit (Table 1).
The relationship between blood biomarkers of dehydration
and change in haemodynamic parameters from baseline to day
1 is shown split by randomization to GTN or no GTN, and stop
or continue prestroke antihypertensive agents (Table 2). There
were no signiﬁcant interactions between treatment with GTN
vs. no GTN and dehydration markers on the change in BP and
heart rate from baseline to day 1. GTN lowered BP and in-
creased heart rate, but dehydration markers did not signiﬁ-
cantly inﬂuence these ﬁndings. Similarly, there were no
signiﬁcant interactions between continuing vs. stopping
prestroke antihypertensive agents and dehydration markers
on haemodynamic changes from baseline to day 1.
We compared the effects of BP-lowering treatment (GTN
vs. no-GTN, and continue vs. stop) on neurological impair-
ment and clinical events during the ﬁrst 7 days and outcome
at 3 months, by level of urea (Table 3) and level of urea : creat-
inine ratio (Table S1). There were no differences in change in
neurological impairment or in rates of reported hypotension,
hypertension or headache by day 7 in those randomized to
GTN compared with no GTN, or those randomized to stop
vs. continue their prestroke antihypertensive agents. In those
with a raised urea (>7.5 mmol l–1), there was a tendency to-
wards an unfavourable shift in mRS and increased death at
90 days when randomized to GTN vs. no GTN (P for interac-
tion = 0.047 and 0.050, respectively), a ﬁnding not seen with
a raised urea : creatinine ratio. No signiﬁcant interactions
were noted in regard to stop vs. continue.
The associations betweenmarkers of dehydration and mRS
anddeath at day 90were assessed across the total available pop-
ulation (Table 4). High urea at baseline was associated with an
unfavourable shift in mRS at day 90 and increased death at
day 90. Although there was no signiﬁcant association between
baseline creatinine and mRS at day 90, increasing creatinine
was associatedwith an increased risk of death at day 90. By con-
trast, a high sodium at baseline was associated with a
favourable shift in mRS at day 90. We did not ﬁnd any signiﬁ-
cant relationships in adjusted analyses between other markers
of dehydration and clinical outcomes at day 90 (Table S2).
The rate of venous thromboembolism by day 7 in the pop-
ulation studied was low (n = 2), and therefore further analysis
to establish any association with markers of dehydration was
not deemed appropriate.
Discussion
In the present preplanned substudy of patients with acute
stroke, measures of dehydration ranged between 1.0% and
Table 1
(Continued)
Participants
All
310 GTN n No GTN n P Continue n Stop n P
Haemoglobin >180 g l–1 (male),
>165 g l–1 (female) (%)
3 (1) 3 (2) 152 0 (0) 142 0.09 1 (1.4) 69 1 (1.4) 70 0.99
Red cell count >6.5 (male),
>5.8 (female) (%)
0 (0) 0 (0) 152 0 (0) 142 – 0 (0) 69 0 (0) 70 –
Osmolarity A: 2Na + Glucose + Urea; Osmolarity B: 2Na + 2K + Glucose+ Urea (mmol l–1). ACE-I, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; bpm, beats per minute; eGFR, estimated glomerular ﬁltration rate; GTN, glyceryl trinitrate; TACS, total anterior cir-
culation syndrome; SSS, Scandinavian Stroke Scale
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55.6%. There was no difference in BP change in dehydrated
patients between those randomized to GTN vs. no GTN, and
between those who continued vs. stopped their prestroke an-
tihypertensive agents. Further, no differences in neurological
status or clinical events at day 7 in dehydrated patients were
seen across randomized groups. In a multivariable analysis,
we found that increased urea was associated with an
unfavourable shift in mRS and more death at day 90 overall.
No consistent ﬁndings were noted for other markers of
dehydration.
Conventional medical teaching suggests that giving
antihypertensive medication, including nitrates, in the con-
text of dehydration may lead to precipitous drops in BP.
However, in this cohort of acute stroke patients, GTN did
not have this effect. This incongruity may stem from the
dose used (5 mg) and route of administration (transdermal),
which is supported by the modest BP-lowering effect seen
across the trial in those randomized to GTN (7/3.5 mmHg
lower after the ﬁrst dose than those randomized to no
GTN) [4]. In addition, continuing prestroke antihyperten-
sive agents did not cause large falls in BP in the context of
dehydration, compared with stopping antihypertensive
agents. The borderline interactions seen in relation to
GTN and mRS and death at day 90 in those with raised urea
are not supported by the neutral effects seen on
haemodynamics across multiple dehydration markers. Such
effects were not seen in those randomized to GTN with
raised urea : creatinine and may, therefore, represent
chance. More data are needed to conﬁrm or refute this
ﬁnding.
Several biochemical markers of dehydration were
assessed using this dataset; only increasing serum urea
was associated with 90-day clinical outcome after acute
stroke. In an earlier observational study of 2042 patients
within 48 h of stroke, raised urea at baseline was associated
with an increased risk of death up to 7 years later [20]. In
addition, raised creatinine and urea : creatinine ratio,
and reduced creatinine clearance, at baseline were associ-
ated with higher mortality risk [20]. Similarly, elevated
urea on admission was associated with a higher mortality
rate during initial hospitalization in a cohort of 388 stroke
patients [21].
Other groups have noted associations between several
markers of dehydration, other than urea, and outcome in
acute stroke. First, an elevated blood urea nitrogen : creati-
nine ratio has been associated with poor neurological out-
come and worse functional outcome in 2570 patients with
acute ischaemic stroke [11]. Similarly, in a UK cohort of
2591 acute stroke patients, a raised urea : creatinine ratio
was associated with an increased likelihood of being dead
or dependent at hospital discharge [10]. Second, elevated
plasma osmolality on admission has been associated with
increased mortality after stroke [12]. Third, reduced base-
line eGFR has been associated with poor functional out-
come after both ischaemic stroke [22] and intracerebral
haemorrhage [23], and long-term mortality and new cardio-
vascular morbidity over a 10-year period in acute stroke
overall [24]. Last, urine speciﬁc gravity has been identiﬁed
as a predictor of early neurological deterioration within
3 days of acute ischaemic stroke [25]. In summary, although
a number of dehydration markers have been associated
with outcome after stroke, there are no consistent ﬁndings
for any particular marker, perhaps reﬂecting that there is
no gold standard measure of dehydration.
The strengths of the present study included the variety of
blood dehydration parameters assessed, and the prespeciﬁed
nature of this analysis within the context of a large random-
ized, controlled trial with almost complete follow-up. Never-
theless, there were certain limitations. First, the data were
limited to two sites and therefore might not be able to be
Table 4
Relationships between baseline markers of dehydration and modiﬁed Rankin Scale (mRS) or death at 3 months. Analysis by ordinal logistic regres-
sion or Cox proportional hazards regression; with adjustment for age, sex, systolic blood pressure, stroke severity (Scandinavian Stroke Scale), time
from onset to randomization, continue/stop and GTN/no GTN. Results are given as odds ratio (OR) or hazard ratio and 95% conﬁdence intervals
Day 90
mRS Death
Unadjusted P Adjusted P Unadjusted P Adjusted P
Sodiuma 0.46 (0.26, 0.81) 0.007 0.49 (0.28, 0.87) 0.015 0.71 (0.30, 1.68) 0.43 0.81 (0.34, 1.93) 0.64
Ureaa 5.31 (2.36, 11.95) <0.001 3.43 (1.42, 8.32) 0.006 3.30 (1.30, 8.38) 0.012 4.55 (1.51, 13.66) 0.007
eGFRa 0.89 (0.81, 0.98) 0.021 0.93 (0.83, 1.04) 0.23 0.90 (0.75, 1.08) 0.27 0.84 (0.68, 1.04) 0.11
Urea : creatinine 1.07 (1.02, 1.11) 0.002 1.03 (0.99, 1.08) 0.13 1.02 (0.97, 1.08) 0.45 1.01 (0.95, 1.08) 0.67
Osmolarity Aa 0.90 (0.67, 1.20) 0.46 0.80 (0.60, 1.09) 0.16 1.21 (0.69, 2.12) 0.51 1.11 (0.65, 1.88) 0.70
Osmolarity Ba 0.88 (0.66, 1.17) 0.38 0.80 (0.60, 1.08) 0.15 1.17 (0.66, 2.08) 0.59 1.10 (0.64, 1.88) 0.74
Haematocritb 0.65 (0.41, 1.05) 0.08 0.74 (0.44, 1.25) 0.26 1.64 (0.79, 3.38) 0.18 1.42 (0.62, 3.26) 0.41
Haemoglobina 0.89 (0.79, 1.01) 0.08 0.92 (0.80, 1.05) 0.21 1.13 (0.93, 1.37) 0.24 1.06 (0.85, 1.34) 0.60
Red cell count 0.94 (0.62, 1.44) 0.79 0.91 (0.58, 1.45) 0.70 1.79 (0.95, 3.36) 0.07 1.60 (0.81, 3.15) 0.18
Signiﬁcant (P < 0.05) results in bold
eGFR, estimated glomerular ﬁltration rate; GTN, glyceryl trinitrate
aOR per 10-unit change
bOR per 0.1 l l–1 change
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extrapolated to larger datasets. Extrapolation to more se-
verely dehydrated stroke patients may not be appropriate as
patients with overt clinical dehydration may have been less
likely to be recruited into ENOS. Further, the relatively small
population studied meant that the analyses of clinical out-
comes, although exploratory, were underpowered, and there-
fore the ﬁndings may represent chance. Second, although
prognostic factors were adjusted for in analyses, we cannot
exclude the possibility that the associations seen were due
to chance or confounded by other factors such as infection,
vomiting, medication and comorbidities. We did not collect
information on ﬂuid supplementation prior to or following
blood being taken, which may have inﬂuenced the partici-
pant’s ﬂuid status, dehydration status and clinical outcomes
measured. Further, diuretic use prestroke has been associated
with dehydration in patients presenting with acute stroke
[10], which may have confounded our results involving the
assessment of GTN vs. no GTN. However, we did not see any
signiﬁcant associations between continuing prestroke anti-
hypertensive agents and outcome in dehydrated stroke pa-
tients in this cohort. Third, no adjustment was made for
multiplicity of testing, and therefore some ﬁndings may rep-
resent chance, highlighted by the opposite directions of asso-
ciation with day 90 outcomes seen for sodium and urea, and
neutral ﬁndings in relation to the creatinine and urea : creati-
nine ratio. Last, whether the negative effects of dehydration
in acute stroke patients are seen in the longer term was not
answered by the present analysis of outcomes assessed at a
relatively early stage poststroke.
In summary, transdermal GTN or continuation of pre-
existing antihypertensive treatment did not cause precipi-
tous drops in BP in dehydrated acute stroke patients. This is
of reassurance and supports the use of GTN in acute stroke
prior to blood markers of dehydration being available. The
ongoing Rapid Intervention with Glyceryl trinitrate in Hy-
pertensive stroke Trial-2 (RIGHT-2) is assessing the safety
and efﬁcacy of GTN in the ambulance within 4 h of symptom
onset and will add to these data in the ultra-acute setting [26].
Dehydration, when measured as urea, was associated with
poor clinical outcomes after acute stroke. Whether rehydra-
tion of dehydrated acute stroke patients has the potential to
improve clinical outcomes requires further assessment in ran-
domized controlled trials.
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